High expression of GSKIP is associated with poor prognosis in meningioma

Meningiomas are the most common extra-axial primary central nervous system tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. glycogen synthesis kinase 3β interaction protein (GSKIP) is an A-kinase anchor protein that has cytosolic scaffoldin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yu-Wen, Chen, Yang-Yi, Lin, Chien-Ju, Lieu, Ann-Shung, Tsai, Hung-Pei, Kwan, Aij-Lie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771170/
https://www.ncbi.nlm.nih.gov/pubmed/36550871
http://dx.doi.org/10.1097/MD.0000000000032209
_version_ 1784854762117660672
author Cheng, Yu-Wen
Chen, Yang-Yi
Lin, Chien-Ju
Lieu, Ann-Shung
Tsai, Hung-Pei
Kwan, Aij-Lie
author_facet Cheng, Yu-Wen
Chen, Yang-Yi
Lin, Chien-Ju
Lieu, Ann-Shung
Tsai, Hung-Pei
Kwan, Aij-Lie
author_sort Cheng, Yu-Wen
collection PubMed
description Meningiomas are the most common extra-axial primary central nervous system tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. glycogen synthesis kinase 3β interaction protein (GSKIP) is an A-kinase anchor protein that has cytosolic scaffolding function and binds to a protein kinase A and glycogen synthesis kinase 3β to modulate different biological processes and malignant tumorigenesis through the Wnt pathway. The purpose of this study was to investigate the relationship between GSKIP expression and the clinico-pathological parameters in meningioma using immunohistochemical staining. We collected samples from 74 patients, from 2008 to 2012, in the Kaohsiung Medical University Hospital that had data on the staging and prognosis of the meningioma pathological section. Chi-square, Kaplan-Meier method, and cox regression were used to analyze the correlation between clinical parameters and immunohistochemistry staining for GSKIP. Following our immunohistochemical score, we found that higher expression of GSKIP was associated with high World Health Organization grading, recurrence, malignant transformation, and reduced overall survival time and recurrence-free survival time in meningioma. GSKIP may be a biomarker of poor prognosis and a target protein for therapy in meningioma.
format Online
Article
Text
id pubmed-9771170
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97711702022-12-22 High expression of GSKIP is associated with poor prognosis in meningioma Cheng, Yu-Wen Chen, Yang-Yi Lin, Chien-Ju Lieu, Ann-Shung Tsai, Hung-Pei Kwan, Aij-Lie Medicine (Baltimore) 4100 Meningiomas are the most common extra-axial primary central nervous system tumors. There is no effective treatment or targeted therapy for meningioma except excision and radiotherapy. glycogen synthesis kinase 3β interaction protein (GSKIP) is an A-kinase anchor protein that has cytosolic scaffolding function and binds to a protein kinase A and glycogen synthesis kinase 3β to modulate different biological processes and malignant tumorigenesis through the Wnt pathway. The purpose of this study was to investigate the relationship between GSKIP expression and the clinico-pathological parameters in meningioma using immunohistochemical staining. We collected samples from 74 patients, from 2008 to 2012, in the Kaohsiung Medical University Hospital that had data on the staging and prognosis of the meningioma pathological section. Chi-square, Kaplan-Meier method, and cox regression were used to analyze the correlation between clinical parameters and immunohistochemistry staining for GSKIP. Following our immunohistochemical score, we found that higher expression of GSKIP was associated with high World Health Organization grading, recurrence, malignant transformation, and reduced overall survival time and recurrence-free survival time in meningioma. GSKIP may be a biomarker of poor prognosis and a target protein for therapy in meningioma. Lippincott Williams & Wilkins 2022-12-16 /pmc/articles/PMC9771170/ /pubmed/36550871 http://dx.doi.org/10.1097/MD.0000000000032209 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4100
Cheng, Yu-Wen
Chen, Yang-Yi
Lin, Chien-Ju
Lieu, Ann-Shung
Tsai, Hung-Pei
Kwan, Aij-Lie
High expression of GSKIP is associated with poor prognosis in meningioma
title High expression of GSKIP is associated with poor prognosis in meningioma
title_full High expression of GSKIP is associated with poor prognosis in meningioma
title_fullStr High expression of GSKIP is associated with poor prognosis in meningioma
title_full_unstemmed High expression of GSKIP is associated with poor prognosis in meningioma
title_short High expression of GSKIP is associated with poor prognosis in meningioma
title_sort high expression of gskip is associated with poor prognosis in meningioma
topic 4100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771170/
https://www.ncbi.nlm.nih.gov/pubmed/36550871
http://dx.doi.org/10.1097/MD.0000000000032209
work_keys_str_mv AT chengyuwen highexpressionofgskipisassociatedwithpoorprognosisinmeningioma
AT chenyangyi highexpressionofgskipisassociatedwithpoorprognosisinmeningioma
AT linchienju highexpressionofgskipisassociatedwithpoorprognosisinmeningioma
AT lieuannshung highexpressionofgskipisassociatedwithpoorprognosisinmeningioma
AT tsaihungpei highexpressionofgskipisassociatedwithpoorprognosisinmeningioma
AT kwanaijlie highexpressionofgskipisassociatedwithpoorprognosisinmeningioma